A malaria vaccine is approved by the World Health Organisation
It reduces the number of severe malaria cases by 30%
MALARIA IS ONE of medical science’s most formidable foes. The search for a vaccine has been going on for decades. Dozens of candidates have been tested in recent years. But so far only one, a jab called RTS,S, made by GlaxoSmithKline, has proved effective in the final stages of clinical trials. On October 6th the World Health Organisation (WHO) recommended RTS,S for use in childhood vaccination in places with transmission of Plasmodium falciparum, the deadliest of the five parasites that cause malaria, and the most common in Africa.
This article appeared in the Science & technology section of the print edition under the headline “Ready to roll”
From the October 9th 2021 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Science & technology
High-tech antidotes for snake bites
Genetic engineering and AI are powering the search for antivenins
Can you breathe stress away?
Scientists are only beginning to understand the links between the breath and the mind
The Economist’s science and technology internship
We invite applications for the 2025 Richard Casement internship
A better understanding of Huntington’s disease brings hope
Previous research seems to have misinterpreted what is going on
Is obesity a disease?
It wasn’t. But it is now
Volunteers with Down’s syndrome could help find Alzheimer’s drugs
Those with the syndrome have more of a protein implicated in dementia